#Industry News
Medical Ventilator
Today 100 GPAINNOVA's RESPIRA emergency ventilators have been delivered to the SEM to continue clinical trial with patients affected by COVID-19 in other hospitals
• RESPIRA emergency ventilation device, developed by GPAINNOVA with the support of Hospital Clínic, Institut de Recerca Germans Trias i Pujol (IGTP) and Facultat de Medicina i Ciències de la Salut de la Universitat de Barcelona, has already passed the first phase of the clinical trial with the first two patients affected by COVID-19, with good results.
• Once the first phase of the trial has been completed, the study can now be extended to other hospitals in the territory and it is for this reason that, thanks to the support received from civil society, companies and administrations, today 100 emergency ventilators are delivered to SEM for its distribution. Barcelona, April 17th 2020. Representatives of Hospital Clínic, Hospital i Institut de Recerca
Germans Trias i Pujol and GPAINNOVA have delivered the first 100 RESPIRA emergency ventilation devices to Centre
d’Operacions Logístiques that has been launched by the Sistema d’Emergències Mèdiques (SEM). The device has already passed the first phase of the clinical study and, with this donation, it can be distributed to other hospitals in Catalonia, depending on the needs, and
the trial can be expanded.
This initiative, along with other prototypes of respirators, has been possible thanks to the support received by a large number of individuals, companies and civil society entities that, through the Fundació Clínic per a la Recerca Biomèdica, have contributed resources. It has also had the support of Servei Català de la Salut, which has encouraged the incorporation of companies and
has supported centers to find this kind of solution.
Clinical trial was carried out with two patients at Hospital Clínic, who have received support for breathing with positive results. These are patients who otherwise would not have had this support.
Once the first phase of the clinical trial has been approved, this trial can be extended to other hospitals in the health system.